Table 1.
Demographic, behavioral, and clinical characteristics of patients diagnosed and followed-up for COVID-19 infection from August 2020 to March 2022 in Armenia.
| Total sample | Asymptomatic + Mild | Moderate + Severe | P value | |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Male | 432 (26.9%) | 256 (26.1%) | 176 (28.3%) | > 0.05 |
| Female | 1170 (73.2%) | 723 (73.9%) | 447 (71.7%) | > 0.05 |
| Age, mean, SE | 47.7 (0.39) | 43.6 (0.48) | 53.6 (0.57) | < 0.05 |
| BMI, n (%) | < 0.05 | |||
| Underweight | 43 (3.8%) | 32 (4.7%) | 11 (2.4%) | |
| Normal | 436 (38.2%) | 287 (41.8%) | 149 (32.7%) | |
| Overweight | 371 (32.5%) | 221 (32.2%) | 150 (33%) | |
| Obese | 292 (25.6%) | 147 (21.4%) | 145 (31.9%) | |
| Blood group, n (%) | > 0.05 | |||
| O | 232 (26.5%) | 137 (26.6%) | 95 (26.2%) | |
| A | 516 (59%) | 308 (59.9%) | 208 (57.5%) | |
| B | 77 (8.8%) | 45 (8.9%) | 32 (8.8%) | |
| AB | 50 (5.7%) | 24 (4.7%) | 26 (7.5%) | |
| Rhesus, n (%) | > 0.05 | |||
| Negative | 187 (20.1%) | 108 (19.8%) | 79 (20.5%) | |
| Positive | 744 (79.9%) | 437 (80.2%) | 307 (79.5%) | |
| Cardiovascular diseases, n (%) | 281 (18.5%) | 140 (15.4%) | 141 (23.3%) | < 0.05 |
| Diabetes melitus, n (%) | 77 (5.1%) | 30 (3.3%) | 47 (7.8%) | < 0.05 |
| COPD, n (%) | 4 (0.3%) | 2 (0.2%) | 2 (0.3%) | > 0.05 |
| Asthma, n (%) | 16 (1.1%) | 9 (1%) | 7 (1.2%) | > 0.05 ara> |
| Autoimmune Thyroiditis, n (%) | 60 (4%) | 36 (4%) | 24 (4%) | > 0.05 |
| Symptoms reported during Covid-19 infection, n (%) | ||||
| Temperature (N = 1508) | 1262 (83.7%) | 733 (81.4%) | 529 (87.2%) | < 0.05 |
| Cough (N = 1507) | 517 (34.3%) | 293 (32.4%) | 224 (36.9%) | > 0.05 |
| Shortness of breath (N = 1508) | 415 (27.5%) | 230 (25.4%) | 185 (30.5%) | < 0.05 |
| Weakness (N = 1508) | 1081 (71.7%) | 613 (68%) | 468 (77.2%) | < 0.05 |
| Body pain (N = 1509) | 734 (48.6%) | 419 (46.3%) | 315 (52%) | < 0.05 |
| Backpain (N = 1507) | 363 (24%) | 199 (22%) | 164 (26.9%) | < 0.05 |
| Diarrhea (N = 1500) | 148 (9.8%) | 71 (7.9%) | 77 (12.6%) | < 0.05 |
| Nausea (N = 1505) | 175 (11.6%) | 88 (9.8%) | 87 (14.3%) | < 0.05 |
| Vomiting (N = 1502) | 73 (4.8%) | 46 (5.1%) | 27 (4.4%) | > 0.05 |
| Headache (N = 1502) | 748 (49.8%) | 429 (47.8%) | 319 (52.7%) | > 0.05 |
| Dizziness (N = 1504) | 503 (33.4%) | 292 (32.5%) | 211 (34.8%) | > 0.05 |
| Muscle pain (N = 1507) | 700 (46.4%) | 400 (44.4%) | 300 (49.2%) | > 0.05 |
| Joint pain (N = 1505) | 428 (28.4%) | 245 (27.2%) | 183 (30.2%) | > 0.05 |
| Disorientation (N = 1504) | 73 (4.9%) | 42 (4.7%) | 31 (5.1%) | > 0.05 |
| Memory loss/disturbance (N = 1506) | 139 (9.2%) | 74 (8.2%) | 65 (10.7%) | > 0.05 |
| Sleep disturbance (N = 1503) | 216 (14.4%) | 116 (12.9%) | 100 (16.4%) | > 0.05 |
| Fear (N = 1500) | 127 (8.5%) | 66 (7.4%) | 61 (10%) | > 0.05 |
| Anxiety (N = 1504) | 103 (6.8%) | 52 (5.8%) | 51 (8.4%) | < 0.05 |
| Depressive symptoms (N = 1505) | 134 (8.9%) | 74 (8.2%) | 60 (9.8%) | > 0.05 |
| Smell/taste disturbance (N = 1506) | 679 (45.2%) | 390 (43.4%) | 289 (47.8%) | > 0.05 |
| Smell/taste loss (N = 1508) | 595 (39.6%) | 331 (36.8%) | 264 (43.6%) | < 0.05 |
| Visual disorder/diplopia (N = 1504) | 50 (3.3%) | 29 (3.2%) | 21 (3.4%) | > 0.05 |
| Speech disturbance (N = 1503) | 37 (2.5%) | 16 (1.8%) | 21 (3.5%) | < 0.05 |
| Swallow disturbance (N = 1506) | 31 (2.1%) | 16 (1.8%) | 15 (2.5%) | > 0.05 |
| Weakness of limbs (N = 1506) | 280 (18.5%) | 157 (17.4%) | 123 (20.2%) | > 0.05 |
| Numbness of face and/or limbs (N = 1508) | 131 (8.7%) | 67 (7.4%) | 64 (10.7%) | < 0.05 |
| Urinary disorder (N = 1507) | 26 (1.7%) | 9 (1%) | 17 (2.8%) | < 0.05 |
| Gait disturbance (N = 1503) | 40 (2.7%) | 16 (1.8%) | 24 (3.9%) | < 0.05 |
| Non-traumatic bruises (N = 1493) | 22 (1.5%) | 15 (1.7%) | 7 (1.2%) | > 0.05 |